Andrew Witty, former CEO of GlaxoSmithKline (NYSE: [[ticker:GSK]]), is moving into biotech investing. Hatteras Venture Partners announced that Witty will become a venture partner at the Durham, NC-based firm. His role will include advising Hatteras’ portfolio companies. Witty left GSK earlier this year after serving as CEO for nine years.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
